Clinical Trials
30 trialsStudy of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
EDO-S101
Mundipharma Research Limited
DUET-3
Xencor, Inc.
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Sierra Oncology LLC - a GSK company
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
E-MOSAIC Electronic Tool to Monitor Symptoms
Swiss Cancer Institute
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
High-dose ICE With Amifostine
Dana-Farber Cancer Institute
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Virginia Commonwealth University
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Memorial Sloan Kettering Cancer Center
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Jonsson Comprehensive Cancer Center
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Study of OSI-930 in Cancer Patients
Astellas Pharma Inc
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NYU Langone Health
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center